«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

32卷

期数:

2026年02期

页码:

101-104

栏目:

专家述评

出版日期:

2026-03-20

文章信息/Info

Title:

Research progress on the mechanism of mesenchymal stem cells and their exosomes in the treatment of ARDS

文章编号:

1006-8147(2026)02-0101-05

作者:

张研¹; 2; 张莹¹; 赵晓赟¹; 3

（1.天津医科大学胸科临床学院，天津300222；2. 天津医科大学第二临床医学院，天津 300211；3. 天津市胸科医院呼吸与危重症医学科，天津300222）

Author(s):

ZHANG Yan¹; 2;  ZHANG Ying¹;  ZHAO Xiaoyun¹; 3

（1. Clinical College of Chest, Tianjin Medical University， Tianjin 300222， China； 2. The Second Clinical Medical College， Tianjin Medical University， Tianjin 300211， China； 3. Department of Respiratory and Critical Care Medicine， Tianjin Chest Hospital， Tianjin 300222， China）

关键词:

间充质干细胞; 急性呼吸窘迫综合征; 免疫调节; 氧化应激; 肺泡-毛细血管屏障; 线粒体转移

Keywords:

-

分类号:

R563

DOI:

10.20135/j.issn.1006-8147.2026.02.0101

文献标志码:

A

摘要:

急性呼吸窘迫综合征（ARDS）是一种高死亡率的危重症，目前尚无特异性疗法。间充质干细胞（MSCs）凭借其强大的免疫调节、组织修复、抗氧化应激等多方面作用机制，成为ARDS治疗领域的研究热点。MSCs治疗ARDS的作用机制包括对免疫细胞的调节作用、抗氧化应激作用、抗细胞死亡作用、促进肺泡-毛细血管屏障修复作用、促进线粒体转移作用、迁移和归巢作用以及调节肺-肠轴作用。关注MSCs治疗ARDS领域的最新研究进展，深入理解MSCs的多靶点机制，可为其临床转化提供坚实依据。

Abstract:

-

参考文献/References:

[1] WICK K D， WARE L B， MATTHAY M A. Acute respiratory distress syndrome[J]. BMJ，2024，387：e076612.
[2] WANG F， XIE C， WANG X. Mesenchymal stem cell therapies for ARDS： translational promise and challenges[J]. Stem Cell Res Ther， 2025， 16（1）： 504.
[3] WANG G， ZHANG Y， HU N， et al. Mesenchymal stem cells attenuate acute lung injury in mice partly by suppressing alveolar macrophage activation in a PGE2-dependent manner[J]. Inflammation， 2022， 45（5）： 2000-2015.
[4] LV H， LIU Q， SUN Y， et al. Mesenchymal stromal cells ameliorate acute lung injury induced by LPS mainly through stanniocalcin-2 mediating macrophage polarization[J]. Ann Transl Med， 2020， 8（6）： 334.
[5] ZHU J， ZHOU J， FENG B， et al. MSCs alleviate LPS-induced acute lung injury by inhibiting the proinflammatory function of macrophages in mouse lung organoid-macrophage model[J]. Cell Mol Life Sci， 2024， 81（1）： 124.
[6] WANG L T， YEN B L， WANG H H， et al. Placental mesenchymal stem cells boost M2 alveolar over M1 bone marrow macrophages via IL-1β in Klebsiella-mediated acute respiratory distress syndrome[J]. Thorax， 2023， 78（5）： 504-514.
[7] NIE Z， FAN Q， JIANG W， et al. Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10/STAT3/NLRP3 axis in acute lung injury[J]. Front Immunol， 2024， 15： 1422355.
[8] GUO X， NIU Z， ZHUANG Y， et al. Bone marrow mesenchymal stromal cells attenuate smoke inhalation injury by regulating the M1/M2-Th17/Treg immune homeostasis axis[J]. Int Immunopharma-col， 2024， 141： 112986.
[9] QIAN H B， ZOU G， LI C， et al. Bone marrow mesenchymal stem cells attenuate LPS-induced acute lung injury in mice by promoting RvE1/ProD1 and modulating Treg/Th17 balance[J]. Turk J Biol， 2022， 46（2）： 173-185.
[10] XUE M， ZHANG X， CHEN J， et al. Mesenchymal stem cell-secreted TGF-β1 restores Treg/Th17 skewing induced by lipopolysaccharide and hypoxia challenge via miR-155 suppression[J]. Stem Cells Int， 2022， 2022： 5522828.
[11] LU Z， CHANG W， MENG S， et al. Mesenchymal stem cells induce dendritic cell immune tolerance via paracrine hepatocyte growth factor to alleviate acute lung injury[J]. Stem Cell Res Ther， 2019， 10（1）： 372.
[12] LU Z， MENG S， CHANG W， et al. Mesenchymal stem cells activate Notch signaling to induce regulatory dendritic cells in LPS-induced acute lung injury[J]. J Transl Med， 2020， 18（1）： 241.
[13] ZHENG J， LI Y， KONG X， et al. Exploring immune-related pathogenesis in lung injury： providing new insights into ALI/ARDS[J]. Biomed Pharmacother， 2024， 175： 116773.
[14] FENG B， FENG X， YU Y， et al. Mesenchymal stem cells shift the pro-inflammatory phenotype of neutrophils to ameliorate acute lung injury[J]. Stem Cell Res Ther， 2023， 14（1）： 197.
[15] SU V Y， LIN C S， HUNG S C， et al. Mesenchymal stem cell-conditioned medium induces neutrophil apoptosis associated with inhibition of the NF-κB pathway in endotoxin-induced acute lung injury[J]. Int J Mol Sci， 2019， 20（9）： 2208.
[16] PENG J， PAN F， XU Y， et al. Mesenchymal stem cell transplantation alleviated TBI-induced lung injury by inhibiting PAD4-dependent NET formation[J]. J Adv Res， 2025，S2090-1232（25）：00438-2.
[17] LEE J， JANG J， PARK S M， et al. An update on the role of Nrf2 in respiratory disease： molecular mechanisms and therapeutic approaches[J]. Int J MolSci， 2021， 22（16）：8406.
[18] LEI L， GUO Y， LIN J， et al. Inhibition of endotoxin-induced acute lung injury in rats by bone marrow-derived mesenchymal stem cells： role of Nrf2/HO-1 signal axis in inhibition of NLRP3 activation[J]. Biochem Biophys Res Commun， 2021， 551： 7-13.
[19] YAN X， FU X， JIA Y， et al. Nrf2/Keap1/ARE signaling mediated an antioxidative protection of human placental mesenchymal stem cells of fetal origin in alveolar epithelial cells[J]. Oxid Med Cell Longev， 2019， 2019： 2654910.
[20] HE X， LI C， YIN H， et al. Mesenchymal stem cells inhibited the apoptosis of alveolar epithelial cells caused by ARDS through CXCL12/CXCR4 axis[J]. Bioengineered， 2022， 13（4）： 9060-9070.
[21] YANG H， LIU Y， YAO J， et al. Mesenchymal stem cells inhibit ferroptosis by activating the Nrf2 antioxidation pathway in severe acute pancreatitis-associated acute lung injury[J]. Eur J Pharmacol， 2024， 967： 176380.
[22] WANG T， ZHANG Z， DENG Z， et al. Mesenchymal stem cells alleviate sepsis-induced acute lung injury by blocking neutrophil extracellular traps formation and inhibiting ferroptosis in rats[J]. PeerJ， 2024， 12： e16748.
[23] RUAN T， HAN J， XUE C， et al. Mesenchymal stem cells protect the integrity of the alveolar epithelial barrier through extracellular vesicles by inhibiting MAPK-mediated necroptosis[J]. Stem Cell Res Ther， 2025， 16（1）： 250.
[24] ZHANG M， XU G， ZHOU X， et al. Mesenchymal stem cells ameliorate H9N2-induced acute lung injury by inhibiting caspase-3-GSDME-mediated pyroptosis of lung alveolar epithelial cells[J]. Eur J Pharmacol， 2023， 960： 176148.
[25] ISHII M， TSUCHIYA T， DOI R， et al. Increased in vitro intercellular barrier function of lung epithelial cells using adipose-derived mesenchymal stem/stromal cells[J]. Pharmaceutics， 2021， 13（8）：1264.
[26] MENG S S， GUO F M， HUANG L L， et al. mTORC2 Activation mediated by mesenchymal stem cell-secreted hepatocyte growth factors for the recovery of lipopolysaccharide-induced vascular endothelial barrier[J]. Stem Cells Int， 2021， 2021： 9981589.
[27] MENG S S， GUO F M， ZHANG X W， et al. mTOR/STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis[J]. J Cell Biochem， 2019， 120（3）： 3637-3650.
[28] ZHAN B， SHEN J. Mitochondria and their potential role in acute lung injury （Review）[J]. ExpTher Med， 2022， 24（1）： 479.
[29] WANG J， MENG S， CHEN Y， et al. MSC-mediated mitochondrial transfer promotes metabolic reprograming in endothelial cells and vascular regeneration in ARDS[J]. Redox Rep， 2025， 30（1）： 2474897.
[30] WANG C， HEZAM K， FU E， et al. In vivo tracking of mesenchymal stem cell dynamics and therapeutics in LPS-induced acute lung injury models[J]. Exp Cell Res， 2024， 437（2）： 114013.
[31] WANG K， DU B， ZHANG Y， et al. Vimentin-Rab7a pathway mediates the migration of MSCs and lead to therapeutic effects on ARDS[J]. Stem Cells Int， 2021， 2021： 9992381.
[32] LV L， CUI E H， WANG B， et al. Multiomics reveal human umbilical cord mesenchymal stem cells improving acute lung injury via the lung-gut axis[J]. World J Stem Cells， 2023， 15（9）： 908-930.
[33] SUN J， DING X， LIU S， et al. Adipose-derived mesenchymal stem cells attenuate acute lung injury and improve the gut microbiota in septic rats[J]. Stem Cell Res Ther， 2020， 11（1）： 384.

相似文献/References:

[1]袁 晴,杜 雪,袁碧波,等.贴壁法和密度梯度离心法分离经血源性子宫内膜间充质干细胞的比较研究[J].天津医科大学学报,2015,21(06):525.
　YUAN Qing,DU Xue,YUAN Bi-bo,et al. ?Comparison of adherence culture method and density gradient centrifugation method in isolating endometrical mensenchymal stem cells isolated from menstrual blood[J].Journal of Tianjin Medical University,2015,21(02):525.
[2]张茹梅 综述,杨万杰 审校.近乎淹溺致急性呼吸窘迫综合征的治疗进展[J].天津医科大学学报,2016,22(04):367.
[3]林源希,宗晓龙,李真玉.复杂性腹腔感染的预后及并发ARDS 的危险因素分析[J].天津医科大学学报,2022,28(03):289.
　LIN Yuan-xi,ZONG Xiao-long,LI Zhen-yu.Prognosis analysis of complicated intra-abdominal infection and risk factor of concurrent ARDS[J].Journal of Tianjin Medical University,2022,28(02):289.
[4]齐颖,陈兵.血清IL-6联合Wnt5a及syndecan-1对急性胰腺炎患者合并急性呼吸窘迫综合征的预测价值[J].天津医科大学学报,2022,28(05):541.
　QI Ying,CHEN Bing.Prognostic value of serum IL-6 combined with Wnt5a and syndecan-1 on ARDS in patients with acute pancreatitis[J].Journal of Tianjin Medical University,2022,28(02):541.
[5]索睿,郝天旭,茹仙古丽·吾买尔 综述,等.间充质干细胞来源的外泌体治疗哮喘的研究进展[J].天津医科大学学报,2023,29(06):673.
[6]郑燕,高伟,孟庆红,等.自体脂肪间充质干细胞对大鼠肝切除术后早期肝再生的促进作用[J].天津医科大学学报,2024,30(02):152.[doi:10.20135/j.issn.1006-8147.2024.02.0152]
　ZHENG Yan,GAO Wei,MENG Qinghong,et al.The promotion of autologous adipose derived mesenchymal stem cells on the early liver regeneration following partial hepatectomy in rats[J].Journal of Tianjin Medical University,2024,30(02):152.[doi:10.20135/j.issn.1006-8147.2024.02.0152]
[7]王彪,陈国强,赵清乾,等.N钙黏蛋白融合蛋白改性表面增强细胞活性与细胞募集能力的研究[J].天津医科大学学报,2024,30(06):509.[doi:10.20135/j.issn.1006-8147.2024.06.0509]
　WANG Biao,CHEN Guoqiang,ZHAO Qingqian,et al.Study on surface modification with N-cadherin fusion protein to enhance cell activity and cell recruitment capability[J].Journal of Tianjin Medical University,2024,30(02):509.[doi:10.20135/j.issn.1006-8147.2024.06.0509]
[8]戴亮,王朔,王钊.多种生存预测评分系统在体外膜肺氧合治疗急性呼吸窘迫综合征患者中的验证研究[J].天津医科大学学报,2026,32(02):112.[doi:10.20135/j.issn.1006-8147.2026.02.0112]
　DAI Liang,WANG Shuo,WANG Zhao.Validation of multiple survival prediction scoring systems in acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation[J].Journal of Tianjin Medical University,2026,32(02):112.[doi:10.20135/j.issn.1006-8147.2026.02.0112]

备注/Memo

备注/Memo:

基金项目 国家临床重点专科建设项目、天津市医学重点学科(TJYXZDXK-3-032C)；天津市科技计划-细胞生态海河实验室揭榜挂帅项目(HH24KYZX0009)；天津市卫生健康科技临床重点专项(TJWJ2024ZK003)
作者简介 张研(2003- )，女，天津医科大学临床"5+3"一体化在读；通信作者：赵晓赟，E-mail：zxydcotor@163.com。

常用功能

更新日期/Last Update: 2026-03-20